Tryz - You and I are tracking 100%. I'd prefer to

Tryz - You and I are tracking 100%. I'd prefer to delay the US launch until the other revenue streams are more mature, the company is profitable and can use revenues from other streams to eliminate or reduce funding needs. And that if funding is required, it is not dilutive or at a minimum, the equity financing occurs with a much higher share price (e.g., above $.50). If J&J renters the market with their product before the RapiMeds US launch, then so be it. No need to rush when then the company has many other solid revenue-generating businesses.